Biotech Roundup: Deals Gone Wrong, Ethical Red Flags & Bay Goodbyes
Xconomy
JUNE 3, 2016
Thousands of others will head to San Francisco for BIO, which has a distinct international flavor. But billions of dollars in acquisitions will be left by the side of the road. Bad FDA news for Teva Pharmaceutical and AstraZeneca also threw outsized acquisitions into question. But the U.S. Teva nabbed deutetrabenazine in its $3.2
Let's personalize your content